Global Bioresorbable Implants Market is estimated to be valued at USD 6.63 Bn in 2025 and is expected to reach USD 11.90 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.7% from 2025 to 2032.
| Report Coverage |
Report Details |
| Base Year: |
2024 |
Market Size in 2025: |
USD 6.63 Bn |
| Historical Data for: |
2020 To 2024 |
Forecast Period: |
2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: |
8.70% |
2032 Value Projection: |
USD 11.90 Bn |
Figure. Bioresorbable Implants Market Share (%), By Region 2025
Bioresorbable implants are medical devices that are designed to remain in the body temporarily and undergo biodegradation after serving their intended purpose. Made from polymers such as polylactic acid (PLLA) and polyglycolic acid (PGA), bioresorbable implants degrade over time and are absorbed by the body. This alleviates the need for subsequent invasive surgery to remove implants. These offer significant benefits over traditional permanent implants by causing less stress shielding, resorbing gradually to transfer load to healing bone, and avoiding long-term complications. Global bioresorbable implants market growth is driven by growing prevalence of cardiac and orthopedic diseases, rising number of surgeries, advantages of bioresorbable materials over permanent implants, and technological advancements.
MARKET DYNAMICS:
Global bioresorbable implants market growth is primarily driven by rising geriatric population who are more prone to develop cardiac diseases and orthopedic disorders. As per WHO, the number of people aged 65 years and above is expected to increase from 524 million in 2010 to nearly 1.5 billion in 2050. Bioresorbable implants reduce the risk of permanent implant-related infections and eliminate the need for implant removal. This boosts their demand over conventional implants. Moreover, advanced resorbable polymers with customized degradation rate are being developed to suit individual tissue healing process, thus, driving the market growth. However, high costs of bioresorbable implants as compared to metal implants and lack of awareness in low-income nations can hamper the market growth. Ongoing R&D to develop resorbable implants for soft tissue repair and drug delivery can offer lucrative opportunities for manufacturers.
Key Features of the Study:
- This report provides in-depth analysis of the global bioresorbable implants market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global bioresorbable implants market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include DePuy Synthes, Stryker, Smith & Nephew, Zimmer Biomet, Medtronic and Bioretec
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global bioresorbable implants market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bioresorbable implants market
Detailed Segmentation-
- By Material Type
- By Application
- Orthopedic
- Cardiovascular
- Others
- By End User
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Others
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Abbott Laboratories
- Medtronic plc
- Johnson & Johnson
- Stryker Corporation
- Zimmer Biomet Holdings, Inc.
- Smith & Nephew plc
- Boston Scientific Corporation
- Biotronik SE & Co. KG
- Terumo Corporation
- Amaranth Medical, Inc.
- Arthrex, Inc.
- Bioretec Ltd.
- REVA Medical, LLC
- Tepha, Inc.
- Corbion N.V.
- DSM Biomedical
- WL Gore & Associates, Inc.
